LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

Home・Aandelen Lijst・Celsion Corp

Celsion Corp

Gesloten

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Belangrijke statistieken
By Trading Economics
Werknemers	25

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+819.12% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	938K
Vorige openingsprijs	0
Vorige sluitingsprijs	0

Celsion Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

30 mrt 2026, 23:15 UTC

Belangrijke Nieuwsgebeurtenissen

U.K. Shoppers Paid a Little More This Month But Worse May yet Lie Ahead

30 mrt 2026, 22:36 UTC

Belangrijke Nieuwsgebeurtenissen

Australian Government Rules Out Boots on the Ground in the Middle East

30 mrt 2026, 22:13 UTC

Acquisities, Fusies, Overnames

Sun Life Financial Agrees to Buy Bell Partners for $350 Million

30 mrt 2026, 21:00 UTC

Winsten

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment

30 mrt 2026, 20:15 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Williams: Middle-East Developments Have Added Significant Economic Uncertainty

30 mrt 2026, 23:40 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

30 mrt 2026, 23:40 UTC

Marktinformatie

Nikkei May Decline on Higher Energy Cost Concerns -- Market Talk

30 mrt 2026, 23:36 UTC

Marktinformatie

Gold Edges Lower Amid Divergent Signals on U.S.-Iran Talks -- Market Talk

30 mrt 2026, 23:12 UTC

Marktinformatie

Alcoa Earnings Outlook Boosted by Market Disruptions -- Market Talk

30 mrt 2026, 22:49 UTC

Marktinformatie

Fed's Williams: Core Inflation Forecast Is Little Changed -- Market Talk

30 mrt 2026, 22:44 UTC

Marktinformatie

Fed's Williams: Risks to Both Sides of Dual Mandate Higher -- Market Talk

30 mrt 2026, 22:43 UTC

Marktinformatie

Fed's Williams Says Focus Is on Inflation Expectations Being Well Anchored -- Market Talk

30 mrt 2026, 22:42 UTC

Marktinformatie

South32 Should Go for Growth, Says New Bull -- Market Talk

30 mrt 2026, 22:18 UTC

Marktinformatie

Paragon Care's Chances of Using Levy to Pass on Higher Costs `Close to Zero' -- Market Talk

30 mrt 2026, 22:05 UTC

Marktinformatie

Northern Star's New Bull Argues Case for Asset Sales -- Market Talk

30 mrt 2026, 21:58 UTC

Acquisities, Fusies, Overnames

Sun Life Financial Agrees to Buy Bell Partners for $350M

30 mrt 2026, 21:39 UTC

Acquisities, Fusies, Overnames

Sun Life Sees 1Q Charge to Net of C$236M From BGO, Crescent Deals

30 mrt 2026, 21:38 UTC

Acquisities, Fusies, Overnames

Sun Life: Completes Remaining Equity Interest Purchases of BGO, Crescent Capital

30 mrt 2026, 21:36 UTC

Acquisities, Fusies, Overnames

Sun Life to Buy Fully Bell Partners for $350M >SLF.T

30 mrt 2026, 21:33 UTC

Acquisities, Fusies, Overnames

Unilever Shareholders Expected to Own Two-Thirds of New Food Entity, Sources Say -- WSJ

30 mrt 2026, 21:33 UTC

Acquisities, Fusies, Overnames

Unilever Nears Deal to Create $60 Billion Food Giant With McCormick -- WSJ

30 mrt 2026, 21:33 UTC

Acquisities, Fusies, Overnames

Deal Could Be Announced As Soon As Tuesday, Sources Say -- WSJ

30 mrt 2026, 21:33 UTC

Acquisities, Fusies, Overnames

Unilever Nears Cash-and-Stock Deal to Combine Food Business With McCormick, Sources Say -- WSJ

30 mrt 2026, 21:33 UTC

Acquisities, Fusies, Overnames

Deal Set to Value Combined Food Business At Around $60B Including Debt, Sources Say -- WSJ

30 mrt 2026, 21:25 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

30 mrt 2026, 21:25 UTC

Marktinformatie

Warehouse Showing Cost Discipline But Margin Goal at Risk -- Market Talk

30 mrt 2026, 21:03 UTC

Acquisities, Fusies, Overnames

Sun Life: Completes Equity Interest Purchases of BGO and Crescent Cap, Announces Acquisition of Bell Partners, a Multifamily Real Estate Investment Manager

30 mrt 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

30 mrt 2026, 20:09 UTC

Winsten

This Stock Looks Like a Solid AI Bet -- and Wall Street Hasn't Noticed Yet -- Barrons.com

30 mrt 2026, 20:00 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Williams: Middle-East Conflict 'Will Likely Boost Overall Inflation in Coming Months'

Peer Vergelijking

Prijswijziging

Celsion Corp Prognose

Koersdoel

By TipRanks

819.12% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 25 USD 819.12%

Hoogste 25 USD

Laagste 25 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Celsion Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Gebaseerd op 1 analisten die aandelenratings hebben gegeven aan Celsion Corp - Dist in de afgelopen 3 maanden.

Financieel

Over Celsion Corp

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.